PRP for Peyronie's Disease

KC
MM
Ranjith Ramasamy, MD profile photo
Overseen ByRanjith Ramasamy, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how Platelet-Rich Plasma (PRP) injections can aid men with Peyronie's Disease (PyD), a condition where scar tissue causes curved and painful erections. The study involves two groups: one receives the PRP treatment first, followed by a placebo (inactive substance), while the other starts with the placebo and later receives the PRP treatment. Men diagnosed with Peyronie's Disease and significant penile curvature may be suitable candidates. Participants must adhere to all study-related tests and procedures. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Do I have to stop taking my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be actively on anticoagulation during the injections, except for aspirin 81 mg, which is allowed.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot be on anticoagulation (blood thinners) during the time of the injections, except for low-dose aspirin (81 mg).

Is there any evidence suggesting that this treatment is likely to be safe for humans?

Research has shown that platelet-rich plasma (PRP) injections are generally safe for treating conditions like Peyronie's Disease. In past studies, patients experienced only minor and temporary side effects, such as mild pain or swelling at the injection site, which resolved on their own. Other research supports the safety of PRP, indicating it is well-tolerated by most people. While more studies are needed to fully confirm these findings, current evidence suggests that PRP is a safe option for those considering joining a clinical trial.12345

Why do researchers think this study treatment might be promising for Peyronie's Disease?

Researchers are excited about using autologous Platelet Rich Plasma (PRP) for treating Peyronie's Disease because it represents a more natural and potentially less invasive option compared to current treatments like surgery or medication. Unlike these traditional methods, PRP is derived from the patient's own blood, which is thought to promote healing by delivering a concentrated dose of growth factors directly to the affected area. This approach not only minimizes the risk of adverse reactions but also leverages the body's own healing mechanisms. Additionally, PRP might offer a quicker recovery time and fewer side effects, making it an attractive alternative for patients seeking relief from this condition.

What evidence suggests that this treatment might be an effective treatment for Peyronie's Disease?

Research shows that using a person's own blood in Platelet-Rich Plasma (PRP) injections might help men with Peyronie's Disease. Studies have found that PRP can improve the shape and thickness of the penis, which are often affected by the disease. This trial will test two different sequences of treatment: one group will receive the Autologous PRP intervention first, followed by a placebo, while the other group will receive the placebo first, followed by the Autologous PRP intervention. The treatment involves taking a sample of the patient's blood to create a concentrated plasma, which may aid healing and reduce scarring. Patients who have tried this treatment reported improvements in the curve of their penis and fewer symptoms. These findings suggest that PRP could be a promising option for those dealing with Peyronie's Disease.26789

Who Is on the Research Team?

MM

Manuel Molina, MD

Principal Investigator

University of Miami

Are You a Good Fit for This Trial?

Men aged 18-75 with Peyronie's Disease, having a penile curvature between 30° and 120°. Candidates must be able to consent, follow study procedures, and have no serious illnesses that affect participation. Excluded are those with hour-glass deformity, prior penile surgeries (other than circumcision), on strong anticoagulants, or unfit for sexual activity.

Inclusion Criteria

Be able to provide written informed consent
Agree to comply with all study related tests/procedures
I have Parkinson's disease with active or stable symptoms.
See 3 more

Exclusion Criteria

I have a planned medical procedure that might affect my PRP therapy.
You have had a previous occurrence of priapism (a painful, prolonged erection) or a penile fracture.
I have not had penile surgery, except for circumcision or condyloma removal.
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either autologous PRP or placebo, followed by crossover to the other intervention after 3 months

6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 month

What Are the Treatments Tested in This Trial?

Interventions

  • Autologous Platelet Rich Plasma
Trial Overview The trial is investigating the effects of injecting Platelet-Rich Plasma (PRP) into men with Peyronie's Disease compared to saline solution injections. The goal is to see if PRP can improve the condition.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Experimental: Placebo followed by Autologous PRP GroupExperimental Treatment2 Interventions
Group II: Experimental: Autologous PRP followed by Placebo GroupExperimental Treatment2 Interventions

Autologous Platelet Rich Plasma is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Platelet-Rich Plasma for:
🇪🇺
Approved in European Union as Platelet-Rich Plasma for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Miami

Lead Sponsor

Trials
976
Recruited
423,000+

Published Research Related to This Trial

Intralesional injection of platelet-rich plasma for Peyronie's disease has shown early signs of safety based on observations from an ongoing clinical trial.
Efficacy data for this treatment are still pending and will be available upon completion of the trial.
A Phase 2 Randomized, Placebo-controlled Crossover Trial to Evaluate Safety and Efficacy of Platelet-rich Plasma Injections for Peyronie's Disease: Clinical Trial Update.Chu, KY., Molina, ML., Ledesma, B., et al.[2023]
In a study of 17 patients receiving platelet rich fibrin matrix (PRFM) injections for urologic conditions, only minor adverse events like mild pain and bruising were reported, indicating a good safety profile.
No decline in erectile function was observed in patients evaluated with the International Index of Erectile Function (IIEF-5) scores, suggesting that PRFM may be a feasible treatment option for erectile dysfunction and other urologic issues.
Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions.Matz, EL., Pearlman, AM., Terlecki, RP.[2022]
In a study involving 17 patients with Peyronie's disease, three intra-platelet-rich plasma (PRP) injections were administered, showing no side effects and significant improvements in the Peyronie's Disease Questionnaire (PDQ) scores after treatment.
The angle of curvature of the penis decreased significantly by 11.8°, and erectile function improved, with the IIEF-EF score increasing by an average of 5 to 7 points at various follow-up intervals, indicating potential efficacy of PRP injections in treating Peyronie's disease.
Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: Pilot study.Schirmann, A., Boutin, E., Faix, A., et al.[2022]

Citations

Platelet-rich plasma in patients affected with Peyronie's ...In this article, we describe the evidence regarding the effectiveness and the safety profile of autologous PRP injections in the treatment of ...
Evaluation of the benefit of using a combination ...Repeated intralesional injections of PRP-HA improve significantly penile deformation and thickening of the TA. This fully natural treatment may stand as a ...
NCT07117955 | Platelet-Rich Plasma for Peyronie's DiseaseA type of clinical study in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may ...
Evaluation of the benefit of using a combination of autologous ...Patient summary: We evaluated here an innovative treatment of Peyronie's disease using intralesional injections of Platelet-Rich Plasma mixed ...
Current insights and future directions in Peyronie's disease ...In this review, we summarize the current knowledge regarding PD, including etiology and epidemiology, diagnosis, management, cutting-edge research, and future ...
Platelet-rich plasma therapy in erectile dysfunction and ...Trials confirm the procedure's safety, noting only minor and temporary adverse events and most seem to indicate small to moderate positive ...
Tolerance and efficacy of platelet-rich plasma injections in ...Conclusion. Our initial experience suggests that PRP injections for Peyronie's disease are safe. Although the limited data is suggestive of efficacy, a placebo ...
Clinical Effects and Safety Outcomes of Platelet-Rich ...Data on study characteristics, PRP protocols, and outcomes using validated erectile function measures and penile Doppler parameters were ...
PRP for Treatment of Peyronie's DiseaseThe purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD). Trial ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security